Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol

Fig. 2

Analysis of first CID events by individual components over 24 weeks (ITT population). *p < 0.05, **p < 0.01, ***p < 0.001. The risk of a first CID event was analyzed using a Cox-Proportional Hazard model including study, treatment group, and smoking status as covariates. AB, aclidinium bromide; CID, clinically important deterioration; FEV1, forced expiratory volume in 1 second; FF, formoterol fumarate; HR, hazard ratio; ITT, intent-to-treat; SGRQ, St George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index

Back to article page